Karolinska Institutet (KI) in Stockholm and AstraZeneca have formed a three-year collaborative research agreement that will apply molecular imaging technologies to generate new diagnostic imaging tools.
KI and the London-based AstraZeneca have collaborated since 2006 in the field of PET imaging of the human brain. This joint venture has led to the invention of several PET ligands and drug development programs.
This collaboration, according to AstraZeneca and the university, will seek to deliver new imaging tools for the diagnosis of patients primarily with severe neurological illnesses, as well as in pain control. In addition, the alliance will facilitate the development of drugs for disorders such as chronic pain, Alzheimer’s disease and Parkinson’s disease.